Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Thiosulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiosulfuric Acid SCHEMBL11200821 | 0.95 | ALDH1A1 (0.50) | MEN1ALDH1A1TSHRKMT2AKDM4E | |
| Thiosulfuric Acid SCHEMBL27724216 | 0.95 | ALDH1A1 (0.50) | MEN1ALDH1A1TSHRKMT2AKDM4E | |
| Thiosulfuric Acid SCHEMBL4088 | 0.95 | — | — | |
| Thiosulfuric Acid SCHEMBL11787332 | 0.95 | ALDH1A1 (0.50) | MEN1ALDH1A1TSHRKMT2AKDM4E | |
| Thiosulfuric Acid SCHEMBL3691097 | 0.90 | MEN1 (0.36) | MEN1ALDH1A1TSHRKMT2A | |
| Sulfuric Acid SCHEMBL3859533 | 0.90 | MEN1 (0.46) | MEN1ALDH1A1TSHRKMT2AKDM4E | |
| Thiosulfuric Acid SCHEMBL3693419 | 0.90 | MEN1 (0.46) | MEN1ALDH1A1TSHRKMT2AKDM4E | |
| Thiosulfuric Acid SCHEMBL8924214 | 0.90 | — | — | |
| Thiosulfuric Acid SCHEMBL3692435 | 0.90 | MEN1 (0.46) | MEN1ALDH1A1TSHRKMT2AKDM4E | |
| Thiosulfuric Acid SCHEMBL144181 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022036259-A1 | PERSONAL ANTIMICROBIAL CARRIER | PAC X, LLC (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20220047050-A1 | PERSONAL ANTIMICROBIAL CARRIER | PAC X, LLC | 2022-02-17 | — | — | US | disclosed |
| US-9480260-B2 | Acrylic polymers containing metallic nanoparticles | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-11-01 | — | — | US | disclosed |
| US-20140288171-A1 | ACRYLIC POLYMERS CONTAINING METALLIC NANOPARTICLES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2014-09-25 | — | — | US | disclosed |
| US-8779023-B2 | In situ formation of nanoparticles in resins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110306699-A1 | IN SITU FORMATION OF NANOPARTICLES IN RESINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2010077985-A1 | IN SITU FORMATION OF NANOPARTICLES IN RESINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-1567101-A4 | PROPHYLACTIC TREATMENT METHODS | NUCRYST PHARM CORP (CA) | 2009-06-03 | — | — | EP | disclosed |
| EP-2043611-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | Nucryst Pharmaceuticals Corp. (CA) | 2009-04-08 | — | — | EP | disclosed |
| US-7427416-B2 | Methods of treating conditions using metal-containing materials | NUCRYST PHARMACEUTICALS CORP. (CA) | 2008-09-23 | — | — | US | disclosed |
| EP-1575552-A2 | METAL-CONTAINING MATERIALS, COMPOSITIONS AND METHODS | Nucryst Pharmaceuticals Corp. (CA) | 2005-09-21 | — | — | EP | disclosed |
| EP-1567101-A2 | PROPHYLACTIC TREATMENT METHODS | NUCFRYST PHARMACEUTICALS CORP. (CA) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005074949-A1 | TREATMENT OF UNGUAL AND SUBUNGUAL DISEASES WITH ANTIMICROBIAL METAL COMPOSITIONS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2005-08-18 | — | — | WO | disclosed |
| US-20040191329-A1 | Compositions and methods of metal-containing materials | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-09-30 | — | — | US | disclosed |
| US-20040176312-A1 | Treatment of ungual and subungual diseases | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-09-09 | — | — | US | disclosed |
| US-20040131698-A1 | Methods of treating conditions using metal-containing materials | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-07-08 | — | — | US | disclosed |
| US-20040129112-A1 | Metal-containing materials | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-07-08 | — | — | US | disclosed |
| US-20040110738-A1 | Prophylactic treatment methods | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-06-10 | — | — | US | disclosed |
| WO-2004037187-A2 | METAL-CONTAINING MATERIALS, COMPOSITIONS AND METHODS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037186-A2 | PROPHYLACTIC TREATMENT METHODS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288171-A1 | ACRYLIC POLYMERS CONTAINING METALLIC NANOPARTICLES | CAD, PUF60, CD63 | MEN1 1997/4885ALDH1A1 1351/4885TSHR 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.